Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression

Cancer Letters

Volumn 321, Issue 2, 2012, Pages 179-186

  Basu, Aninda ^a,c   Liu, Tao ^a,c,f   Banerjee, Pallavi ^a,c   Flynn, Evelyn ^a,c   Zurakowski, David ^b,c   Datta, Dipak ^a,c,g   Viklicky, Ondrej ^d   Gasser, Martin ^e   Waaga Gasser, Ana Maria ^e   Yang, Jun ^a,c,h   Pal, Soumitro ^a,c  

^a Division of Nephrology and Transplantation Research Center   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g CENTRAL DRUG RESEARCH INSTITUTE   (India)

^h HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Angiogenesis; Chemokine; Renal cancer; Transplantation; VEGF

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CYCLOSPORIN A; CYTOKINE; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; S6 KINASE; TACROLIMUS; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY ALLOGRAFT REJECTION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; CALCINEURIN; CELL LINE, TUMOR; CHEMOKINES; DOWN-REGULATION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; RECEPTORS, CXCR3; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE;

EID: 84862778506     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.004     Document Type: Article

References (43)

1. Kasiske B.L., Snyder J.J., Gilbertson D.T., Wang C. Cancer after kidney transplantation in the United States. Am. J. Transplant. 2004, 4:905-913.
2. Bustami R.T., Ojo A.O., Wolfe R.A., Merion R.M., Bennett W.M., McDiarmid S.V., Leichtman A.B., Held P.J., Port F.K. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am. J. Transplant. 2004, 4:87-93.
3. Lutz J., Heemann U. Tumours after kidney transplantation. Curr. Opin. Urol. 2003, 13:105-109.
4. Wimmer C.D., Rentsch M., Crispin A., Illner W.D., Arbogast H., Graeb C., Jauch K.W., Guba M. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007, 71:1271-1278.
5. Dantal J., Soulillou J.P. Immunosuppressive drugs and the risk of cancer after organ transplantation. New Engl. J. Med. 2005, 352:1371-1373.
6. Campistol J.M. Minimizing the risk of cancer in transplant patients. G. Ital. Nefrol. 2010, 27(Suppl 50):S81-85.
7. Webster A.C., Craig J.C., Simpson J.M., Jones M.P., Chapman J.R. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am. J. Transplant. 2007, 7:2140-2151.
8. Gutierrez-Dalmau A., Campistol J.M. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007, 67:1167-1198.
9. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., Shimbo T., Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397:530-534.
10. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., Jauch K.W., Geissler E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 2002, 8:128-135.
11. Basu A., Contreras A.G., Datta D., Flynn E., Zeng L., Cohen H.T., Briscoe D.M., Pal S. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res. 2008, 68:5689-5698.
12. Guba M., Graeb C., Jauch K.W., Geissler E.K. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004, 77:1777-1782.
13. Maluccio M., Sharma V., Lagman M., Vyas S., Yang H., Li B., Suthanthiran M. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003, 76:597-602.
14. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
15. Basu A., Datta D., Zurakowski D., Pal S. Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J. Biol. Chem. 2010, 285:25196-25202.
16. Zlotnik A. Chemokines in neoplastic progression. Semin. Cancer Biol. 2004, 14:181-185.
17. Zipin-Roitman A., Meshel T., Sagi-Assif O., Shalmon B., Avivi C., Pfeffer R.M., Witz I.P., Ben-Baruch A. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res. 2007, 67:3396-3405.
18. Walser T.C., Rifat S., Ma X., Kundu N., Ward C., Goloubeva O., Johnson M.G., Medina J.C., Collins T.L., Fulton A.M. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 2006, 66:7701-7707.
19. Suyama T., Furuya M., Nishiyama M., Kasuya Y., Kimura S., Ichikawa T., Ueda T., Nikaido T., Ito H., Ishikura H. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Cancer 2005, 103:258-267.
20. Datta D., Contreras A.G., Grimm M., Waaga-Gasser A.M., Briscoe D.M., Pal S. Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J. Am. Soc. Nephrol. 2008, 19:2437-2446.
21. Datta D., Contreras A.G., Basu A., Dormond O., Flynn E., Briscoe D.M., Pal S. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res. 2009, 69:8902-8909.
22. Monaco A.P. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009, 87:157-163.
23. Geissler E.K., Schlitt H.J. The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int. 2010, 78:1075-1079.
24. Koehl G.E., Andrassy J., Guba M., Richter S., Kroemer A., Scherer M.N., Steinbauer M., Graeb C., Schlitt H.J., Jauch K.W., Geissler E.K. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004, 77:1319-1326.
25. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 2004, 4:335-348.
26. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I.G., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R.J. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl. J. Med. 2007, 356:2271-2281.
27. Basu A., Banerjee P., Contreras A.G., Flynn E., Pal S. Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. PLoS One 2011, 6:e23919.
28. Vander Haar E., Lee S.I., Bandhakavi S., Griffin T.J., Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell. Biol. 2007, 9:316-323.
29. Choueiri T.K., Bukowski R.M., Rini B.I. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Semin. Oncol. 2006, 33:596-606.
30. Pan F., Sun L., Kardian D.B., Whartenby K.A., Pardoll D.M., Liu J.O. Feedback inhibition of calcineurin and Ras by a dual inhibitory protein carabin. Nature 2007, 445:433-436.
31. Carriere A., Romeo Y., Acosta-Jaquez H.A., Moreau J., Bonneil E., Thibault P., Fingar D.C., Roux P.P. ERK1/2 phosphorylate Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). J. Biol. Chem. 2011, 286:567-577.
32. Han W., Ming M., He T.C., He Y.Y. Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J. Biol. Chem. 2010, 285:11369-11377.
33. Leseux L., Laurent G., Laurent C., Rigo M., Blanc A., Olive D., Bezombes C. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 2008, 111:285-291.
34. Minhajuddin M., Bijli K.M., Fazal F., Sassano A., Nakayama K.I., Hay N., Platanias L.C., Rahman A. Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells. J. Biol. Chem. 2009, 284:4052-4061.
35. Mireuta M., Darnel A., Pollak M. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors 2010, 28:243-255.
36. Harada H., Itasaka S., Kizaka-Kondoh S., Shibuya K., Morinibu A., Shinomiya K., Hiraoka M. The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J. Biol. Chem. 2009, 284:5332-5342.
37. Pal S., Datta K., Khosravi-Far R., Mukhopadhyay D. Role of protein kinase Czeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J. Biol. Chem. 2001, 276:2395-2403.
38. Goldberg-Bittman L., Neumark E., Sagi-Assif O., Azenshtein E., Meshel T., Witz I.P., Ben-Baruch A. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol. Lett. 2004, 92:171-178.
39. Datta D., Flaxenburg J.A., Laxmanan S., Geehan C., Grimm M., Waaga-Gasser A.M., Briscoe D.M., Pal S. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res. 2006, 66:9509-9518.
40. Reinders M.E., Sho M., Izawa A., Wang P., Mukhopadhyay D., Koss K.E., Geehan C.S., Luster A.D., Sayegh M.H., Briscoe D.M. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J. Clin. Invest. 2003, 112:1655-1665.
41. Melillo R.M., Castellone M.D., Guarino V., De Falco V., Cirafici A.M., Salvatore G., Caiazzo F., Basolo F., Giannini R., Kruhoffer M., Orntoft T., Fusco A., Santoro M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 2005, 115:1068-1081.
42. Whaley J.M., Naglich J., Gelbert L., Hsia Y.E., Lamiell J.M., Green J.S., Collins D., Neumann H.P., Laidlaw J., Li F.P., et al. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am. J. Hum. Genet. 1994, 55:1092-1102.
43. Chang Y.S., Adnane J., Trail P.A., Levy J., Henderson A., Xue D., Bortolon E., Ichetovkin M., Chen C., McNabola A., Wilkie D., Carter C.A., Taylor I.C., Lynch M., Wilhelm S. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharmacol. 2007, 59:561-574.